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Following the development of the infection-and-treatment method of immuniza
tion against East Coast fever (ECF) by the United Nations Development
Programme/Food and Agriculture Organization of the United Nations group at
the East African Veterinary Research Organisation, now the National Veterinary
Research Centre (NVRC), in Muguga, Kenya, between 1967 and 1977, the
Kenya Government was reluctant to sanction the extensive field use of the
method. The following concerns were expressed.
a) Immunized cattle might show a reduction in productivity.
b) Insufficient information was available on the various Theileria parva para
sites prevalent in the country.
c) Theileria parva parasites from cattle would not protect cattle against buf
falo-derived parasite stocks.
d) Immunized animals might become carriers and thus introduce alien strains
of parasites into previously uninfected regions of the country.
IMMUNIZATION REPORTS
e) The infection-and-treatment immunization method might be impractical
and/or unsafe.
Since then, work in various laboratories has been undertaken to address these
concerns. Presently, a Kenya/British project based at NVRC, Muguga, has been
charged with the safe implementation of large-scale ECF immunization in the
country. We report here on some laboratory studies carried out, focussing on
some of the concerns listed above.
SAFETY STUDIES ON THE INFECTION-AND-
TREATMENT IMMUNIZATION
Studies to determine safe and optimal immunizing sporozoite doses for a num
ber of T. p. parva and T. p. lawrencei stocks were carried out, as well as investi
gations on the efficacy of treatment with the available immunizing drugs. The
studies involved inoculating groups of susceptible Friesian cattle with various
doses of T. parva sporozoite stabilate dilutions, either singly or in combination.
The infections were then treated with one of three anti-theilerial drugs:
Medamycin 100 (TechAmerica Group, Inc.), a short-acting oxytetracycline;
Terramycin LA (Pfizer Ltd., U.K.), a long-acting oxytetracycline; or a new
chemotherapeutic drug, buparvaquone (ButalexR, Coopers Animal Health).
Medamycin was given at 10 mg/kg on days 0 and 4 of the immunization.
Terramycin LA was given at 20 mg/kg at the same time as stabilate inoculation,
and buparvaquone was given at 2.5 mg/kg also at the same time as stabilate
inoculation. All drugs were injected intramuscularly.
Following sporozoite stabilate inoculation and appropriate drug treatment, the
immunization reaction was monitored using daily clinical and parasitological
observations (theilerial schizont parasitosis). On days 28 and 35 after immu
nization, surviving cattle were examined for T. parva antibodies using the indi
rect fluorescent antibody test (Burridge and Kimber, 1972). On about day 60
after immunization, the surviving cattle were challenged with a lethal dose of
homologous parasite. These cattle were later challenged with heterologous par
asites.
The results for five titration experiments involving various T. parva stocks
from geographically separated areas of Kenya are summarized in Table 1 . In the
titration involving T. p. lawrencei (01 Pejeta) stabilate 199, the highest concen
tration of 1.0 ml of undiluted stabilate could not be satisfactorily controlled by
either Terramycin LA or Medamycin 100. However, at lower concentration
(1:100), it was possible to induce subclinical theileriosis with the development
of antibodies to T. parva. These cattle were immune to homologous challenge.
Bupavaquone controlled higher concentrations of the stabilate better than the
two oxytetracycline formulations. In contrast, both oxytetracyclines controlled
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undiluted and 1:80 stabilate concentrations of the T. p. parva (Marikebuni)
stock. However, cattle inoculated with the lower dilutions of this parasite stock,
as well as surviving controls, were not immune to homologous challenge. The
significance of this is discussed later.
Table 1 . Reactions of cattle receiving titrated doses of various Theileria parva stabi-
lates and treatment with either Medamycin 100 at 10 mg/kg on days 0 and
4, Terramycin LA at 20 mg/kg on day 0 or buparvaquone at 2.5 mg/kg on
day 0
Parasite
stock
Drug
treatments
Cattle reaction
(survived immunization)/D28
Undiluted 1:10 1:100 1: 1000
T. p. lawrencei (01 Pejeta)
(Stabilate 1 99)
No drug
Terramycin LA
Medamycin 100
Buparvaquone
0/3
1/3
0/3
1/3
1/3
2/3
3/3
3/3
1/3 3/3(2)
3/3
3/3
8/8
1:5 1:10 1:100
T. p. lawrencei (Mara III)
(Stabilate 202)
and
No drug 0/3 1/3
T. p. parva (Kilae)
(Stabilate 1 87)
Terramycin LA 2/3 2/3 3/3
Medamycin 100 2/3 3/3 3/3
Undiluted 1:10 1:100
T. p. lawrencei (Mara III)
(Stabilate 202)
No drug — — 2/3(1)
T. p. parva (Kilae)
(Stabilate 187)
No drug — — 3/3 (3)
Undiluted 1:10 1:80
7. p. parva (Marikebuni) No drug 0/5 4/4 (2) 5/5 (4)
(Stabilate 3014) Terramycin LA
Medamycin 100
5/5
5/5
5/5(1)+
5/5
5/5 (2)*
5/5(1)*
( ) Not immune to homologous challenge.
( )* Negative serology after immunization (D35).
( )+ Positive serology after immunization.
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Immunization using mixed T. parva stocks, T. p. parva (Kilae) stabilate 187
and a T. p. lawrencei (Mara III) stabilate 202, worked well. Mixed concentra
tions of these stabilates at 1:10 and 1:100 dilutions were controlled satisfactorily
by both formulations of oxytetracyclines. In a separate titration, stabilate 202
was shown to be more virulent than stabilate 187. Theileria parva carrier states
were demonstrated in some oxytetracycline-immmunized cattle, but not in bu-
parvaquone-treated animals. Both T. p. parva and T. p. lawrencei stocks were
shown to produce the carrier state.
CROSS-IMMUNITY STUDIES
Since the advent of the infection-and-treatment immunization method, re
searchers have searched for a T. parva stock capable of conferring a wide pro
tection against challenge with other theilerial parasites. An alternative approach
was to combine several theilerial parasite stocks to form an "immunization unit"
with wide protection. Such a combination of parasites exemplified by the
"Muguga cocktail" can be used with a measure of success, as demonstrated in
several countries. Recently, Irvin et al. (1983) isolated a theilerial parasite stock,
referred to as T. p. parva (Marikebuni), from Kilifi District, Kenya, which was
shown to provide good protection against severe challenge with other stocks
isolated from the district. As the stock is well characterized, it was decided to
use this isolate in cross-immunity studies with other T. parva isolates from
widely separated areas of Kenya.
Table 2 lists the T. parva isolates from Kenya used in the studies. Eight of
these isolates (all T. p. parva) were from Kilifi District, Coast Province, Kenya.
Five other stocks, two of T. p. parva and three of T. p. lawrencei, were isolates
from the Rift Valley Province, Kenya. One isolate, T. p. parva (Mbita), was
from Nyanza Province and three new isolates, Kil, Ki3 and Ki4, were from
Kiambu District, Central Province. The isolation location for each isolate is
indicated on the map of Kenya (Figure 1). The isolates were used in cross-im
munity studies to challenge cattle immune to the T. p. parva (Marikebuni) stock.
The experimental studies required the generation of T. p. parva (Marikebuni)
immune cattle by immunizing groups of Friesian steers with selected doses of
the stabilate and treating the steers with either Medamycin or Terramycin LA.
Groups of the Marikebuni immune cattle were challenged in the following ways:
a) challenge of Marikebuni immune cattle by other coastal T. p. parva stocks
from Kilifi District
b) challenge of Marikebuni immune cattle with T. p. parva and T. p. lawren
cei stocks from elsewhere in Kenya
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c) challenge of cattle immune to T. p. parva and T. p. lawrencei stocks from
elsewhere in Kenya with a lethal dose of T. p. parva (Marikebuni)
The reactions of the experimental cattle on challenge were described as
"inapparent" where no macroschizonts were detected, "mild" where low num
bers of schizonts were detected transiently and where a transient fever may or
may not have been observed, and "severe" where prolonged schizont parasitosis
occurred, usually in high numbers for several days and accompanied by fever.
"Very severe" reactions were those where high schizont parasitosis was
recorded with a marked development of fever, usually resulting in death. Cattle
with inapparent and mild reactions were considered immune. Those with severe
and very severe reactions were regarded as not immune, irrespective of whether
the animal died.
ETHIOPIA
 
Figure 1. The locations in Kenya where Theileria parva stocks were iso
lated for use in cross-immunity studies. The key to the locations
is given in Table 2.
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The results of the cross-immunity experiments are shown in Table 2. Thei-
leria p. parva (Marikebuni) immune cattle were protected against challenge with
seven T. p. parva stocks from Kilifi District and four T. p. parva stocks from
other areas of Kenya and showed partial protection against challenge by T. p.
lawrencei stocks. Furthermore, cattle immune to various T. parva stocks were
protected against lethal challenge with T. p. parva (Marikebuni).
Table 2. Theileria parva stocks used in cross-immunity experiments
Coast Province
1. 7. p. parva (Mariakani) Stabilate 3029
2. T. p. parva (Utange) Stabilate 223
3. T. p. parva (Mtwapa) Stabilate 2262
4. T. p. parva (Kilifi) Stabilate 1015
5. T. p. parva (Kibarani) Stabilate 2448
6. T. p. parva (Kiswani) Stabilate 2240
7. T. p. parva (Magarini) Stabilate 2365
8. T. p. parva (Junju) Stabilate 1086
9. T. p. parva (Marikebuni) Stabilate 3014
Rift Valley Province
10. T. p. parva (Uasin Gishu 6) Stabilate 216
11. T. p. parva (Kilae) Stabilate 1 87
12. T. p. lawrencei (Mara III) Stabilate 202
13. T. p. lawrencei (Ngongl) Stabilate 2306
14. T. p. lawrencei (01 Pejeta) Stabilate 1 99
Nyanza Province
15. T. p. parva (Mbita) Stabilate 1 69
Central Province
16. T. p. parva (Ki1) Stabilate 210
17. T. p. parva (Ki3) Stabilate 213
18. T. p. parva (Ki4) Stabilate 214
Note: See Figure 1 showing location of isolation site.
From the titration and cross-immunity studies the following observations
were made.
a) There was an optimal range of sporozoite dose for each stabilate that could
be controlled satisfactorily by the antitheilerial drugs, which produced sub
clinical theilerial reactions, and the cattle were immune to homologous
challenge. Sporozoite concentrations above the optimal dose produced se
vere theilerial reactions and those below either did not infect cattle (as
shown by lack of T. parva antibodies) or infected cattle with only a propor
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tion of the antigenic components of the stabilate. Such cattle were subse
quently shown to be susceptible to homologous challenge. This was prob
ably the result of certain parasite components not being present at these
very high dilutions.
b) It was possible to immunize cattle with virulent T. p. lawrencei stocks
(stabilate 199 killed cattle at 1:1000 dilution), provided the right dilution
was selected together with the right combination of drug dose and treat
ment regimen.
c) Mixed T. p. parva and T. p. lawrencei parasites could be combined and
used in various concentrations in immunization.
d) The use of buparvaquone in immunization with the more difficult T. p.
lawrencei stocks may be justified in special cases, but for routine T. p.
parva immunization, especially on a large scale, oxytetracyclines are the
drugs of choice. Two doses of Medamycin were comparable to one dose of
Terramycin LA, but in the T. parva (Marikebuni) titration, the short-acting
drug gave slightly superior results. The Medamycin treatment regimen was
also cheaper, but required that the animals be mustered twice.
e) Cattle immunized with the T. p. parva (Marikebuni) stock were protected
against parasites from the Rift Valley, Central and Nyanza provinces and
did not break through the immunity provided by T. parva stocks from
geographically separated areas of Kenya. Theileria p. parva (Marikebuni)
could provide a master immunizing stock for cattle-derived theileriosis in
Kenya.
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